Skip to main content
Erschienen in: Drugs & Aging 2/2019

17.12.2018 | Leading Article

Parkinson’s Disease in the Era of Personalised Medicine: One Size Does Not Fit All

Erschienen in: Drugs & Aging | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The concept of personalised medicine in Parkinson’s disease has arrived where the implications of findings made in research are certain to have an increasing impact upon clinical practice. Disease heterogeneity in Parkinson’s disease has been well described and lends itself to the construct of personalised medicine where it is hypothesised that a greater understanding of genetic and pathophysiological contributions may underpin the sub-groups described. This in turn has driven the development of potentially individualised disease-modifying therapies where, for example, we are beginning to see treatments that target patients with Parkinson’s disease with specific genetic mutations. Furthermore, clinicians are increasingly recognising the need to tailor their management approach to patients depending on their age of presentation, acknowledging differential side-effect profiles and responses especially when considering the use of device-assisted technologies such as infusion or surgery. Clearly, individualising the treatment of both motor and non-motor symptoms will remain imperative but, in the future, personalised medicine may provide clearer insights into various aspects of a patient’s symptomatology, disease course and thus the best therapeutic approaches.
Literatur
1.
Zurück zum Zitat Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–87.CrossRefPubMed Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277–87.CrossRefPubMed
2.
Zurück zum Zitat Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord. 2017;32(9):1264–310.CrossRefPubMedPubMedCentral Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord. 2017;32(9):1264–310.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Titova N, Padmakumar C, Lewis SJ, et al. Parkinson’s: a syndrome rather than a disease? J Neural Transm (Vienna). 2017;124(8):907–14.CrossRef Titova N, Padmakumar C, Lewis SJ, et al. Parkinson’s: a syndrome rather than a disease? J Neural Transm (Vienna). 2017;124(8):907–14.CrossRef
4.
Zurück zum Zitat Ehgoetz Martens KA, Shine JM, Walton CC, et al. Evidence for subtypes of freezing of gait in Parkinson’s disease. Mov Disord. 2018;33(7):1174–8.CrossRefPubMed Ehgoetz Martens KA, Shine JM, Walton CC, et al. Evidence for subtypes of freezing of gait in Parkinson’s disease. Mov Disord. 2018;33(7):1174–8.CrossRefPubMed
5.
Zurück zum Zitat Mu J, Chaudhuri KR, Bielza C, et al. Parkinson’s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front Aging Neurosci. 2017;9:301.CrossRefPubMedPubMedCentral Mu J, Chaudhuri KR, Bielza C, et al. Parkinson’s disease subtypes identified from cluster analysis of motor and non-motor symptoms. Front Aging Neurosci. 2017;9:301.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Lawton M, Baig F, Rolinski M, et al. Parkinson’s disease subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J Parkinsons Dis. 2015;5(2):269–79.CrossRefPubMedPubMedCentral Lawton M, Baig F, Rolinski M, et al. Parkinson’s disease subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J Parkinsons Dis. 2015;5(2):269–79.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343–8.CrossRefPubMedPubMedCentral Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343–8.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One. 2013;8(8):e70244.CrossRefPubMedPubMedCentral Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One. 2013;8(8):e70244.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Szeto JY, O’Callaghan C, Shine JM, et al. The relationships between mild cognitive impairment and phenotype in Parkinson’s disease. NPJ Parkinsons Dis. 2015;1:15015.CrossRefPubMedPubMedCentral Szeto JY, O’Callaghan C, Shine JM, et al. The relationships between mild cognitive impairment and phenotype in Parkinson’s disease. NPJ Parkinsons Dis. 2015;1:15015.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson’s disease. Brain. 2009;132(Pt 11):2947–57.CrossRefPubMed Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson’s disease. Brain. 2009;132(Pt 11):2947–57.CrossRefPubMed
12.
Zurück zum Zitat Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. Edinburgh: Elsevier/Saunders; 2011. p. 548 (vii). Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. Edinburgh: Elsevier/Saunders; 2011. p. 548 (vii).
13.
Zurück zum Zitat Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature. 2017;546(7660):656–61.CrossRefPubMedPubMedCentral Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature. 2017;546(7660):656–61.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson’s disease. Neuroscience. 2015;302:89–102.CrossRefPubMed Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson’s disease. Neuroscience. 2015;302:89–102.CrossRefPubMed
15.
16.
17.
Zurück zum Zitat Atashrazm F, Hammond D, Perera G, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease. Sci Rep. 2018;8(1):15446.CrossRefPubMedPubMedCentral Atashrazm F, Hammond D, Perera G, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease. Sci Rep. 2018;8(1):15446.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Titova N, Chaudhuri KR. Personalized medicine and nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:1257–81.CrossRefPubMed Titova N, Chaudhuri KR. Personalized medicine and nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:1257–81.CrossRefPubMed
20.
Zurück zum Zitat Antonini A, Moro E, Godeiro C, et al. Medical and surgical management of advanced Parkinson’s disease. Mov Disord. 2018;33(6):900–8.CrossRefPubMed Antonini A, Moro E, Godeiro C, et al. Medical and surgical management of advanced Parkinson’s disease. Mov Disord. 2018;33(6):900–8.CrossRefPubMed
22.
Zurück zum Zitat Silberstein P, Bittar RG, Boyle R, et al. Deep brain stimulation for Parkinson’s disease: Australian referral guidelines. J Clin Neurosci. 2009;16(8):1001–8.CrossRefPubMed Silberstein P, Bittar RG, Boyle R, et al. Deep brain stimulation for Parkinson’s disease: Australian referral guidelines. J Clin Neurosci. 2009;16(8):1001–8.CrossRefPubMed
23.
Zurück zum Zitat Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease: clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023–30.CrossRefPubMed Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease: clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023–30.CrossRefPubMed
24.
25.
26.
Zurück zum Zitat Schrag A, Hovris A, Morley D, et al. Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250–6.CrossRefPubMed Schrag A, Hovris A, Morley D, et al. Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250–6.CrossRefPubMed
27.
Zurück zum Zitat Calne SM, Kumar A. Young onset Parkinson’s disease: practical management of medical issues. Parkinsonism Relat Disord. 2008;14(2):133–42.CrossRefPubMed Calne SM, Kumar A. Young onset Parkinson’s disease: practical management of medical issues. Parkinsonism Relat Disord. 2008;14(2):133–42.CrossRefPubMed
28.
Zurück zum Zitat Seier M, Hiller A. Parkinson’s disease and pregnancy: an updated review. Parkinsonism Relat Disord. 2017;40:11–7.CrossRefPubMed Seier M, Hiller A. Parkinson’s disease and pregnancy: an updated review. Parkinsonism Relat Disord. 2017;40:11–7.CrossRefPubMed
29.
Zurück zum Zitat Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther. 2007;29(9):1825–49.CrossRefPubMed Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther. 2007;29(9):1825–49.CrossRefPubMed
30.
Zurück zum Zitat Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121–7.CrossRefPubMed Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121–7.CrossRefPubMed
31.
Zurück zum Zitat Lenka A, Padmakumar C, Pal PK. Treatment of older Parkinson’s disease. Int Rev Neurobiol. 2017;132:381–405.CrossRefPubMed Lenka A, Padmakumar C, Pal PK. Treatment of older Parkinson’s disease. Int Rev Neurobiol. 2017;132:381–405.CrossRefPubMed
32.
Zurück zum Zitat Lewis SJ, Gangadharan S, Padmakumar CP. Parkinson’s disease in the older patient. Clin Med (Lond). 2016;16(4):376–8.CrossRef Lewis SJ, Gangadharan S, Padmakumar CP. Parkinson’s disease in the older patient. Clin Med (Lond). 2016;16(4):376–8.CrossRef
33.
Zurück zum Zitat Meng Y, Voisin MR, Suppiah S, et al. Is there a role for MR-guided focused ultrasound in Parkinson’s disease? Mov Disord. 2018;33(4):575–9.CrossRefPubMed Meng Y, Voisin MR, Suppiah S, et al. Is there a role for MR-guided focused ultrasound in Parkinson’s disease? Mov Disord. 2018;33(4):575–9.CrossRefPubMed
34.
Zurück zum Zitat Williams DR, Evans AH, Fung VS, et al. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia. Intern Med J. 2017;47(10):1107–13.CrossRefPubMed Williams DR, Evans AH, Fung VS, et al. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia. Intern Med J. 2017;47(10):1107–13.CrossRefPubMed
35.
Zurück zum Zitat Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord. 2009;24(12):1803–10.CrossRefPubMed Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord. 2009;24(12):1803–10.CrossRefPubMed
36.
Zurück zum Zitat Lewis SJ. Disease-modifying approaches for Parkinson disease. Med J Aust. 2018;208(9):377–8.CrossRefPubMed Lewis SJ. Disease-modifying approaches for Parkinson disease. Med J Aust. 2018;208(9):377–8.CrossRefPubMed
37.
Zurück zum Zitat Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28(5):668–70.CrossRefPubMed Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28(5):668–70.CrossRefPubMed
40.
Zurück zum Zitat Thaler A, Bregman N, Gurevich T, et al. Parkinson’s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord. 2018;55:45–9.CrossRefPubMed Thaler A, Bregman N, Gurevich T, et al. Parkinson’s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord. 2018;55:45–9.CrossRefPubMed
41.
Zurück zum Zitat Ferreira M, Massano J. An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol Scand. 2017;135(3):273–84.CrossRefPubMed Ferreira M, Massano J. An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol Scand. 2017;135(3):273–84.CrossRefPubMed
42.
Zurück zum Zitat O’Regan G, deSouza RM, Balestrino R, et al. Glucocerebrosidase mutations in Parkinson disease. J Parkinsons Dis. 2017;7(3):411–22.CrossRefPubMed O’Regan G, deSouza RM, Balestrino R, et al. Glucocerebrosidase mutations in Parkinson disease. J Parkinsons Dis. 2017;7(3):411–22.CrossRefPubMed
43.
Zurück zum Zitat Nyholm D. Duodopa® treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012;18(8):916–29.CrossRefPubMed Nyholm D. Duodopa® treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord. 2012;18(8):916–29.CrossRefPubMed
44.
Zurück zum Zitat Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749–59.CrossRefPubMed Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749–59.CrossRefPubMed
Metadaten
Titel
Parkinson’s Disease in the Era of Personalised Medicine: One Size Does Not Fit All
Publikationsdatum
17.12.2018
Erschienen in
Drugs & Aging / Ausgabe 2/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0624-5

Weitere Artikel der Ausgabe 2/2019

Drugs & Aging 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.